A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC
Part of paid clinical trials in Fort Myers, Florida.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT02451930
- Phase
- PHASE1
- Status
- Completed
Conditions
- Stage IV Non-Small Cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Necitumumab — DRUGAdministered IV
- Pembrolizumab — DRUGAdministered IV
Study Details
The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).
Key Dates
- Start date
- Sep 4, 2015
- Status verified
- Oct 2019
- Primary completion
- Jan 26, 2017
- Completion
- Sep 17, 2019
Study Design
- Enrollment
- 71 participants (actual)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Necitumumab + PembrolizumabPart A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab: Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies). Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab: Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology. Part C were Japan participants. Part C were Japan participants.
Primary Outcome Measure
Number of Participants With Dose Limiting Toxicities (DLTs) in Part A and Part C [ Time Frame: Baseline through Cycle 1 (21 day cycles) ]
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | - |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | - |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | - |
Find similar trials in Fort Myers, FL
Related Studies
- A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerPHASE1/PHASE2 · Recruiting · Iovance Biotherapeutics, Inc. · Los Angeles, California
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCPHASE1 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Bay City, Michigan
- Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung CancerRecruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio